Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ASND
ASND
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ASND News
RBC Capital Markets Lists 13 Biotechs Likely to Attract Takeover Interest
Mar 19 2026
seekingalpha
Ascendis Pharma Reports Positive Phase 2 Trial Results for TransCon hGH
Mar 18 2026
NASDAQ.COM
FDA Grants Approvals for Multiple New Therapies
Mar 06 2026
NASDAQ.COM
Ascendis Pharma Plans 2026 U.S. Launch of YUVIWEL Following FDA Approval
Mar 05 2026
Yahoo Finance
Ascendis Pharma A/S (ASND.US) Officer Plans to Sell $4.44 Million in Common Stock via Form 144
Mar 02 2026
moomoo
Ascendis Pharma Receives FDA Approval for New Drug
Mar 02 2026
Benzinga
Ascendis Pharma Receives FDA Accelerated Approval for YUVIWEL
Feb 28 2026
NASDAQ.COM
FDA Approves Ascendis Pharma's Yuviwel for Dwarfism Treatment
Feb 28 2026
seekingalpha
FDA Approves First Treatment for Achondroplasia
Feb 27 2026
Newsfilter
Ascendis Pharma Receives FDA Approval for YUVIWEL, a Breakthrough Treatment for Achondroplasia
Feb 27 2026
Yahoo Finance
Perceptive Advisors Acquires 431,432 Shares of Praxis Precision Medicines
Feb 22 2026
Yahoo Finance
Perceptive Advisors Increases Stake in Celcuity
Feb 22 2026
Yahoo Finance
BridgeBio Pharma Stock Soars on Positive Clinical Trial Results
Feb 12 2026
Benzinga
Ascendis Pharma Reports Strong 2025 Financial Results and Growth Outlook
Feb 12 2026
Yahoo Finance
Ascendis Pharma Reports Strong FY Earnings, Surpassing Expectations
Feb 11 2026
seekingalpha
Ascendis Pharma Reports Strong 2025 Financial Results and Growth Outlook
Feb 11 2026
Yahoo Finance
Show More News
